Today’s Stock Market in 2-Minutes
August 21, 2026
-
-
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
August 21, 2026
-
Foresight Evaluates Expansion into New Technology Markets, Including AI-Based Technologies, Cybersecurity and Data Centers
August 21, 2026
-
reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform
August 21, 2026
-
Top News
- Professional Diversity Network Launches PDN Intelligence to Advance GPU-Powered AI Infrastructure August 21, 2026
- Asure Expands Enterprise Payroll Tax and Treasury Solutions Via the 330,000-Customer AWS Marketplace August 21, 2026
- Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval August 21, 2026
- Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives August 21, 2026
Axe Compute (NASDAQ AGPU) 2026 Q2 Earnings Call
Watch the replay of Axe Compute's Second Quarter 2026 earnings conference call, originally held live on Monday, August 17, 2026 at 8:30 a.m. Eastern Time. Christopher Miglino, Chief Executive Officer; Kyle Okamoto, President; and Jeremy Yaukey-Witter, Chief Financial Officer, review the Company's Q2 2026 financial results, recent business developments, and priorities for the second half of 2026. Key highlights discussed on the call: Revenue grew more than 90x sequentially in the Company's first full quarter of compute operations Customer prepayments grew from $0.8 million to $60.8 million, with $17.4 million in operating cash flow in the first half of 2026 The $260 million dedicated cluster of 2,304 NVIDIA B300 GPUs progressed through build, targeted for Q3 2026 go-live Total 2026 signed contracted value now exceeds $3 billion Read the full press release and financial statements on Axe Compute's investor website.
August 17, 2026Popular Reads
-
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH – – Potential for Up to an Additional $100 Million Upon FDA Approval of Seralutinib – – Financing Includes Participation from Existing Shareholders and Leading Healthcare Investors – SAN DIEGO–(BUSINESS WIRE)–Aug. 21, 2026– Gossamer Bio, Inc. (Nasdaq: GOSS) (the […]
August 21, 2026
-
Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives
Company Reviewing Multiple Opportunities BOCA RATON, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. (OTCQB: SBIG) (the “Company”) today provided an update regarding its recently completed reorganization and its ongoing review of strategic alternatives designed to create long-term value for stockholders. Under the previously announced reorganization, the Company transferred ownership of its former operating subsidiary […]
August 21, 2026
-
Algorhythm Holdings Announces Strategic Review and Evaluation of Potential Business Combination in Data Center Energy Infrastructure Sector
Company Currently Evaluating Potential Acquisition of Energy Infrastructure Company Focused on Power Generation for Data Centers Fort Lauderdale, FL, Aug. 19, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company” or “Algorhythm”) (NASDAQ: RIME) – a leading provider of AI-powered logistics solutions, today announced that its Board of Directors has authorized management to evaluate strategic alternatives intended […]
August 19, 2026
-
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and […]
August 21, 2026
News
-
Today’s Stock Market in 2-Minutes
August 21, 2026
-
Elevra Lithium Completes Binding Supply Agreement with Mangrove Lithium
August 21, 2026
-
LivePerson Reminds Stockholders of Additional Time to Vote FOR SoundHound AI Transaction
August 21, 2026
-
Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives
August 21, 2026
-
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
August 21, 2026
-
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
August 21, 2026
-
CROSS TIMBERS ROYALTY TRUST DECLARES AUGUST CASH DISTRIBUTION
August 21, 2026
-
Asure Expands Enterprise Payroll Tax and Treasury Solutions Via the 330,000-Customer AWS Marketplace
August 21, 2026